Compass Therapeutics announced that it completed enrollment of the planned 150 patients in COMPANION-002, its randomized Phase 2/3 clinical trial of CTX-009 in patients with BTC. “We are very pleased to announce this enrollment milestone for the COMPANION-002 trial. We extend our deep gratitude to all the patients, families, and caregivers who are participating in the study. We would also like to thank the principal investigators, study coordinators, the Cholangiocarcinoma Foundation, and the clinical team at Compass for their dedicated support and hard work.” said Thomas Schuetz, MD, PhD, Co-founder, CEO, and Vice Chairman of the Compass Board of Directors.